AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Short Bowel Syndrome - Pipeline Review, H2 2019 - ResearchAndMarkets.com

January 9, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 9, 2020--

The “Short Bowel Syndrome - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 3, 1, 7 and 1 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kqsequ

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005582/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: GENERAL HEALTH HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/09/2020 10:31 AM/DISC: 01/09/2020 10:31 AM

http://www.businesswire.com/news/home/20200109005582/en